NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
19
NBY Quote, Financials, Valuation and Earnings
Last price:
$0.50
Seasonality move
:
-0.66%
Day range:
$0.50 - $0.53
52-week range:
$0.36 - $9.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.06x
P/B ratio:
2.43x
Volume:
514.1K
Avg. volume:
111K
1-year change:
-94.45%
Market cap:
$2.6M
Revenue:
$14.7M
EPS (TTM):
-$35.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals
|
$2.6M | -$0.31 | -60.77% | -99.16% | -- |
|
IBIO
iBio
|
-- | -$0.46 | -100% | -89.82% | -- |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | -- |
|
PTN
Palatin Technologies
|
-- | -$0.51 | -100% | -25% | -- |
|
TOVX
Theriva Biologics
|
-- | -$5.25 | -- | -8.25% | $100.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals
|
$0.53 | -- | $2.6M | -- | $0.00 | 0% | 0.06x |
|
IBIO
iBio
|
$2.48 | -- | $22.7M | -- | $0.00 | 0% | -- |
|
NNVC
Nanoviricides
|
$1.49 | -- | $21.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$0.36 | -- | $4.3M | -- | $0.00 | 0% | 1.40x |
|
PTN
Palatin Technologies
|
$0.97 | -- | $18.9M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.14 | $100.00 | $3.2M | -- | $0.00 | 0% | 0.90x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.704 | 1.51% | 0.75x |
|
IBIO
iBio
|
4.41% | 6.097 | 5.41% | 3.89x |
|
NNVC
Nanoviricides
|
-- | 2.114 | -- | -- |
|
OGEN
Oragenics
|
-- | 5.927 | -- | -- |
|
PTN
Palatin Technologies
|
-- | -0.872 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -1.027 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
IBIO
iBio
|
-- | -$4.1M | -90.99% | -148.3% | -1820.57% | -$3.7M |
|
NNVC
Nanoviricides
|
-- | -$3.2M | -- | -- | -- | -$2.6M |
|
OGEN
Oragenics
|
-- | -$2.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
$350K | -$7.8M | -- | -- | -2356.3% | -$7M |
|
TOVX
Theriva Biologics
|
-- | -$5M | -- | -- | -- | -$3.9M |
NovaBay Pharmaceuticals vs. Competitors
-
Which has Higher Returns NBY or IBIO?
iBio has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of -4444.57%. NovaBay Pharmaceuticals's return on equity of -461.38% beat iBio's return on equity of -148.3%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M IBIOiBio-- -$0.46 $22.3M -
What do Analysts Say About NBY or IBIO?
NovaBay Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 602.96%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that NovaBay Pharmaceuticals has higher upside potential than iBio, analysts believe NovaBay Pharmaceuticals is more attractive than iBio.
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals0 0 0 IBIOiBio0 0 0 -
Is NBY or IBIO More Risky?
NovaBay Pharmaceuticals has a beta of 0.686, which suggesting that the stock is 31.383% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.
-
Which is a Better Dividend Stock NBY or IBIO?
NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or IBIO?
NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than iBio quarterly revenues of $175K. NovaBay Pharmaceuticals's net income of -$1.2M is higher than iBio's net income of -$4M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.06x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M IBIOiBio-- -- $175K -$4M
-
Which has Higher Returns NBY or NNVC?
Nanoviricides has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M NNVCNanoviricides-- -$0.23 -- -
What do Analysts Say About NBY or NNVC?
NovaBay Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 602.96%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 336.24%. Given that NovaBay Pharmaceuticals has higher upside potential than Nanoviricides, analysts believe NovaBay Pharmaceuticals is more attractive than Nanoviricides.
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals0 0 0 NNVCNanoviricides0 0 0 -
Is NBY or NNVC More Risky?
NovaBay Pharmaceuticals has a beta of 0.686, which suggesting that the stock is 31.383% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.355%.
-
Which is a Better Dividend Stock NBY or NNVC?
NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or NNVC?
NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Nanoviricides quarterly revenues of --. NovaBay Pharmaceuticals's net income of -$1.2M is higher than Nanoviricides's net income of -$3.1M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.06x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M NNVCNanoviricides-- -- -- -$3.1M
-
Which has Higher Returns NBY or OGEN?
Oragenics has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M OGENOragenics-- -$0.38 -- -
What do Analysts Say About NBY or OGEN?
NovaBay Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 602.96%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 25237.83%. Given that Oragenics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Oragenics is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals0 0 0 OGENOragenics0 0 0 -
Is NBY or OGEN More Risky?
NovaBay Pharmaceuticals has a beta of 0.686, which suggesting that the stock is 31.383% less volatile than S&P 500. In comparison Oragenics has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.551%.
-
Which is a Better Dividend Stock NBY or OGEN?
NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or OGEN?
NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Oragenics quarterly revenues of --. NovaBay Pharmaceuticals's net income of -$1.2M is higher than Oragenics's net income of -$2.5M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.06x versus 1.40x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M OGENOragenics1.40x -- -- -$2.5M
-
Which has Higher Returns NBY or PTN?
Palatin Technologies has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of -2357.27%. NovaBay Pharmaceuticals's return on equity of -461.38% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M PTNPalatin Technologies-- -$0.39 -$111.5K -
What do Analysts Say About NBY or PTN?
NovaBay Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 602.96%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than NovaBay Pharmaceuticals, analysts believe Palatin Technologies is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals0 0 0 PTNPalatin Technologies0 0 0 -
Is NBY or PTN More Risky?
NovaBay Pharmaceuticals has a beta of 0.686, which suggesting that the stock is 31.383% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.
-
Which is a Better Dividend Stock NBY or PTN?
NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or PTN?
NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Palatin Technologies quarterly revenues of $350K. NovaBay Pharmaceuticals's net income of -$1.2M is higher than Palatin Technologies's net income of -$7.8M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.06x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M PTNPalatin Technologies-- -- $350K -$7.8M
-
Which has Higher Returns NBY or TOVX?
Theriva Biologics has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M TOVXTheriva Biologics-- -$6.81 -- -
What do Analysts Say About NBY or TOVX?
NovaBay Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 602.96%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 7838.6%. Given that Theriva Biologics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Theriva Biologics is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals0 0 0 TOVXTheriva Biologics1 0 0 -
Is NBY or TOVX More Risky?
NovaBay Pharmaceuticals has a beta of 0.686, which suggesting that the stock is 31.383% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.
-
Which is a Better Dividend Stock NBY or TOVX?
NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or TOVX?
NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Theriva Biologics quarterly revenues of --. NovaBay Pharmaceuticals's net income of -$1.2M is higher than Theriva Biologics's net income of -$7.7M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.06x versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M TOVXTheriva Biologics0.90x -- -- -$7.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 1.23% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.25% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.65% over the past day.
